1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Chronic Disease Analysis & Statistics 2021 - Europe (p40)

Chronic Disease Analysis & Statistics 2021 - Europe (p40)

1171-1200 of about 1500 reports

2018 Dilated Cardiomyopathy Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Dilated Cardiomyopathy Market

  • $ 999
  • June 2018
  • 70 pages

Dilated cardiomyopathy is a heart related disease in which the left ventricle enlarges and thereby becomes thin. This results in reduce efficiency of the heart to do its regular pumping activity. It is ...

  • Europe
  • United States
  • Cardiovascular Disease
  • Therapy
  • Industry analysis
  • Mortality Rate

Ireland in 2030: The Future Demographic

  • $ 912
  • June 2018
  • 16 pages

In 2030, the population of Ireland will reach 5.2 million, an increase of 8.1% from 2017. Strong, albeit declining, natural change will be responsible for the majority of this relatively strong growth, ...

  • Ireland
  • Healthcare
  • Urban Development
  • Country analysis
  • Life Expectancy
  • Urban Population

Intravascular Temperature Management Market by Type, - Global Forecasts to 2022

  • $ 4950
  • November 2017
  • 125 pages

The intravascular temperature management market is expected to register a CAGR of 3.6% during the next five years. The intravascular temperature management market is expected to register a CAGR of 3.6% ...

  • Europe
  • World
  • Intensive Care
  • Pathology
  • Industry analysis
  • Health Expenditure
  • Hospital Admission

Market Access Impact (EU5) [T2DM] (Injectables)

  • $ 5637
  • November 2017
  • 1 pages

Find out why doctors can’t prescribe your brand, and what you can do about it Market barriers affect just over a fifth of prescriptions for injectable treatments for Type 2 Diabetes Mellitus in the ...

  • Spain
  • France
  • Type 2 Diabetes
  • Insulin
  • Industry analysis

EpiCast Report: Macular Edema - Epidemiology Forecast to 2026

  • $ 3995
  • November 2017
  • 42 pages

EpiCast Report: Macular Edema - Epidemiology Forecast to 2026 Summary Macular edema (ME) is a condition characterized by the thickening and swelling (edema) of the macula, which is the area of the retina ...

  • United States
  • Spain
  • Type 2 Diabetes
  • Industry analysis
  • Diabetes Prevalence
  • Hospital Occupancy Rate

Market Access Impact (EU5) [RA]

  • $ 5637
  • November 2017
  • 1 pages

Eliminating market barriers could help one brand almost double its market share Market barriers have a modest but significant effect on rheumatoid arthritis (RA) prescriptions in the EU5. The brands ...

  • Spain
  • France
  • Monoclonal Antibody
  • Arthritis
  • Industry analysis

Market Access Impact (EU5) [T2DM] (Orals)

  • $ 2844
  • November 2017
  • 1 pages

Find out why doctors can’t prescribe your brand, and what you can do about it Market barriers affect just under a fifth of prescriptions for oral treatments for Type 2 Diabetes Mellitus in the EU5 ...

  • World
  • Spain
  • Type 2 Diabetes
  • Gliptins
  • Industry analysis

Global Cardiovascular Ultrasound Market Research Report Insights, Opportunity Analysis, Market Shares and Forecast, 2017 - 2023

  • $ 3900
  • October 2017
  • 190 pages

An ultrasound system creates images known as sonograms. The global cardiovascular ultrasound system market is expected to rise at a CAGR of 6% during the forecast period 2016-2023. The key factor contributing ...

  • World
  • Europe
  • Healthcare
  • Cardiology
  • Industry analysis
  • Health Expenditure

Soft Drinks: The future lies beyond sugar

  • $ 495
  • August 2018
  • 13 pages

Soft Drinks: The future lies beyond sugar Summary Some major new trends are sweeping through the beverage industry and they are having a major impact on both manufacturers and consumers. For the soft ...

  • United Kingdom
  • Beverage
  • Juice
  • Industry analysis
  • Sugar Consumption
  • Health Insurance Claims

EUROPE CARDIOVASCULAR ULTRASOUND SYSTEM MARKET 2018 -2026

  • $ 1425
  • March 2018
  • 95 pages

KEY FINDINGS The Europe cardiovascular ultrasound system market is predicted to dominate the global scene by the end of the forecast period of 2018-2026. Over these estimated years, the market is anticipated ...

  • Europe
  • Germany
  • Cardiology
  • Research And Development
  • Industry analysis

EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2026

  • $ 3995
  • October 2017
  • 50 pages

EpiCast Report: Pulmonary Arterial Hypertension - Epidemiology Forecast to 2026 Summary Pulmonary arterial hypertension (PAH) is a rare and severe condition characterized by vascular proliferation and ...

  • United States
  • France
  • Hypertension
  • Industry analysis
  • Mortality Rate
  • Diabetes Prevalence

Abionic SA - Product Pipeline Analysis, 2018 Update

  • $ 750
  • June 2018
  • 31 pages

Summary Abionic SA (Abionic) is a medical device company that develops, produces, and markets in vitro diagnostic devices.The company provides products such as abioSCOPE, IVD capsule, abioGUIDE, abioGUIDE ...

  • Europe
  • Switzerland
  • Clinical Trial
  • Diabetes Monitoring
  • Industry analysis
  • Cause-Specific Mortality Rate
  • Medical Devices Sales

UCB S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

  • $ 350
  • July 2018
  • 206 pages

UCB S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline’s UCB S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes ...

  • United States
  • New York
  • Pharmaceutical
  • Financial Services
  • Investor presentation
  • Company
  • Drug Approval
  • Pharmaceutical Exports

Belarus in 2030: The Future Demographic

  • $ 912
  • May 2018
  • 16 pages

In 2030, the population of Belarus will reach 9.3 million, a decrease of 1.8% from 2017. Population decline over this period will be driven by increasingly negative natural change, with births declining ...

  • Belarus
  • Diabetes
  • Country analysis
  • Net Migration Rate
  • Life Expectancy

EPIOMIC EPIDEMIOLOGY SERIES: ACUTE DECOMPENSATED HEART FAILURE FORECAST IN 12 MAJOR MARKETS 2017-2027

  • $ 4808
  • October 2017
  • 53 pages

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Acute Decompensated Heart Failure in 12 Major Markets Acute decompensated heart failure (ADHF), a sub-set of chronic heart failure ...

  • United States
  • India
  • Heart Failure
  • Cardiovascular Disease
  • Industry analysis
  • Hospital Admission
  • Hospital Expenditure

Value Added Services in Cardiometabolic Diseases -- Payer views

  • $ 2537
  • October 2017
  • 1 pages

Pharma’s Value-Added Services (VAS) in cardiometabolic disease are not universally appreciated – why? Too often, useful programmes to monitor, educate and support patients are quietly dropped post ...

  • United States
  • European Union
  • Pharmaceutical
  • Chronic Disease
  • Industry analysis

Breo Ellipta

  • $ 10000
  • July 2018
  • 41 pages

Drug Overview Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Fluticasone ...

  • Japan
  • Germany
  • Respiratory Disease
  • Hormone
  • Industry analysis

Daliresp

  • $ 10000
  • July 2018
  • 16 pages

Drug Overview Daliresp (roflumilast; AstraZeneca/Allergan/Takeda) is an oral phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of patients with severe chronic obstructive pulmonary disease ...

  • Japan
  • United States
  • Respiratory Disease
  • Industry analysis

Duaklir Pressair

  • $ 10000
  • July 2018
  • 18 pages

Drug Overview Duaklir Pressair ([aclidinium + formoterol]; AstraZeneca/Circassia/Kyorin Pharmaceutical) is a twice-daily fixed-dose combination of the long-acting beta 2 agonist formoterol and the long-acting ...

  • United States
  • Japan
  • Healthcare
  • Respiratory Disease
  • Industry analysis

Incruse

  • $ 10000
  • July 2018
  • 16 pages

Drug Overview Incruse (umeclidinium; GlaxoSmithKline) is a once-daily long-acting muscarinic antagonist (LAMA) indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive ...

  • United States
  • European Union
  • Respiratory Disease
  • Hospital
  • Industry analysis

Advair

  • $ 10000
  • July 2018
  • 37 pages

Drug Overview Advair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) is a fixed-dose combination of an inhaled corticosteroid (fluticasone propionate) and a long-acting beta 2 agonist (salmeterol). ...

  • Europe
  • Japan
  • Pulmonary Delivery
  • Asthma
  • Industry analysis

Anoro

  • $ 10000
  • July 2018
  • 20 pages

DRUG OVERVIEW GlaxoSmithKline and Theravance (now Innoviva) developed the once-daily inhaled combination, Anoro, consisting of umeclidinium and vilanterol for the treatment of chronic obstructive pulmonary ...

  • Japan
  • European Union
  • Respiratory Disease
  • Hospital
  • Industry analysis

Cimzia

  • $ 10000
  • July 2018
  • 65 pages

Drug Overview Cimzia (certolizumab; UCB/Astellas [also marketed by Dermira in some approved indications]) is a PEGylated humanized monoclonal antibody fragment, with high affinity for both soluble and ...

  • United States
  • European Union
  • Monoclonal Antibody
  • Autoimmune Disease
  • Industry analysis

Nucala

  • $ 10000
  • July 2018
  • 27 pages

Drug Overview Nucala (mepolizumab; GlaxoSmithKline) is a humanized monoclonal immunoglobulin G1 antibody that binds to interleukin (IL)-5, which plays a significant role in the activation, proliferation, ...

  • Japan
  • United States
  • Asthma
  • Monoclonal Antibody
  • Industry analysis

Stiolto Respimat

  • $ 10000
  • July 2018
  • 21 pages

Drug Overview Stiolto Respimat ([olodaterol + tiotropium]; Boehringer Ingelheim) is a fixed-dose combination of the long-acting beta 2 agonist (LABA) olodaterol and the gold-standard long-acting muscarinic ...

  • United States
  • European Union
  • Respiratory Treatment
  • Healthcare
  • Industry analysis

Seebri Neohaler

  • $ 10000
  • July 2018
  • 17 pages

Drug Overview Novartis, under license from Vectura and Sosei, developed Seebri Neohaler, a once-daily inhaled formulation of glycopyrrolate. The once-daily long-acting muscarinic antagonist (LAMA) received ...

  • United States
  • Japan
  • Respiratory Disease
  • Healthcare
  • Industry analysis

Striverdi Respimat

  • $ 10000
  • July 2018
  • 16 pages

Drug Overview Striverdi (olodaterol; Boehringer Ingelheim) is a long-acting beta 2 agonist delivered via the Respimat inhaler. It is indicated for the once-daily maintenance treatment of airflow obstruction ...

  • Japan
  • United States
  • Respiratory Disease
  • Hospital
  • Industry analysis

Symbicort

  • $ 10000
  • July 2018
  • 30 pages

Drug Overview AstraZeneca’s Symbicort ([budesonide + formoterol]) was the second inhaled corticosteroid/long-acting beta 2 agonist (ICS/LABA) drug combination to launch on the respiratory market, starting ...

  • Japan
  • United States
  • Pharmaceutical
  • Respiratory Treatment
  • Industry analysis

Tudorza Pressair

  • $ 10000
  • July 2018
  • 17 pages

Drug Overview Tudorza Pressair (aclidinium; AstraZeneca/Circassia/Kyorin Pharmaceutical) is a twice-daily long-acting muscarinic antagonist indicated for the maintenance treatment of chronic obstructive ...

  • Europe
  • Japan
  • Respiratory Disease
  • Industry analysis

Trimbow

  • $ 10000
  • July 2018
  • 17 pages

Drug Overview Trimbow ([beclomethasone + formoterol + glycopyrrolate]; Chiesi Farmaceutici) is a fixed triple-combination product consisting of glycopyrrolate (a LAMA), formoterol (a LABA), and beclometasone ...

  • Europe
  • Generic Drug
  • Respiratory Disease
  • Industry analysis

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on